Last reviewed · How we verify
NCT01035632
Study of Smoking Abstinence
trial in Substance Abuse Disorders in 210 participants. Completed in 12 January 2011.
Quick facts
| Lead sponsor | National Institute on Drug Abuse (NIDA) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 210 |
| Start date | 7 April 2006 |
| Estimated completion | 12 January 2011 |
| Sites | 1 location across United States |
Conditions studied
- Substance Abuse Disorders — all drugs for Substance Abuse Disorders →
Sponsor
National Institute on Drug Abuse (NIDA)
Who can join
18 and older, any sex, with Substance Abuse Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: \- Relapse following cigarette abstinence remains a common problem for smokers who are attempting to quit. Most research has focused on the acute withdrawal phase that occurs within the first 48 hours to 1 week after quitting; however, more information is needed on the experiences of smokers in longer durations of abstinence. Objectives: * To study the effects of long-term smoking abstinence. * To study the effects of cigarette-related cues on craving in longer periods of smoking abstinence. Eligibility: \- Individuals at least 18 years of age who are current smokers (at least 10 cigarettes per day) and who want to quit but are not currently attempting to quit. Design: * Participants will be randomly assigned to abstain from all nicotine use for 7, 14, or 35 days. A fourth group of participants will also abstain for 35 days, but will undergo more testing sessions than the other groups. * All participants will have an initial orientation session in which they will complete questionnaires about their smoking habits and will respond to smoking-related cues to provide information about their cravings. * Participants will visit the clinic daily during their abstinence period, and provide urine and breath samples to test for tobacco use. Participants will receive compensation for every day that they do not use tobacco. * On the end day of the abstinence period, participants will return to the clinic, provide urine and breath samples, and undergo testing of their responses to smoking-related cues. Participants in the fourth group will have these tests on Days 7, 14, and 35 of abstinence; other participants will have the tests only once, at the end of their abstinence period. * After the required abstinence period, participants will enter a 5-day step-down period. They will continue to report to the clinic for breath and urine testing, and they will receive payments for abstinence that decrease in value across days. * After the step-down period, for the final 12 days of the study, participants will report to the clinic every 3 days to give urine and breath samples and to report the number of cigarettes smoked.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01035632
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Substance Abuse Disorders
Currently open trials in the same condition.
- NCT06837662 — The MOUD Plus Pilot: Counseling and Peer Support to Support Retention for Medically Complex Patients With Opioid Use Dis · NA · recruiting
Other National Institute on Drug Abuse (NIDA) trials
Trials by the same sponsor.
- NCT07468552 — Trial of Tirzepatide for the Treatment of Cannabis Use Disorder · Phase 2 · not yet recruiting
- NCT06808932 — VK4-116 Phase I Study With Food-Effect · Phase 1 · not yet recruiting
- NCT06676059 — SMART-r: Substance Monitoring and Active Relapse Tracking Repository · recruiting
- NCT06577454 — Measuring the Effects of Neurostimulation on Risky and Ambiguous Decision-Making Capacity in People With and Without Sub · NA · suspended
- NCT06868914 — Phase I Trial of High-Density Theta Burst Stimulation (hdTBS) · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01035632 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA)
- Last refreshed: 2 July 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01035632.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing